HTFL
Heartflow, Inc. Common StockHTFL
HTFL
About: HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.
–
Funds holding %
of 7,335 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for HTFL.
Financial journalist opinion
Based on 11 articles about HTFL published over the past 30 days
Neutral
GlobeNewsWire
14 hours ago
Heartflow, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
MOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its upsized initial public offering of 19,166,667 shares of its common stock at a public offering price of $19 per share, which includes 2,500,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares of common stock were offered by Heartflow. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Heartflow, were approximately $364.2 million. Heartflow's common stock began trading on the Nasdaq Global Select Market on August 8, 2025 under the ticker symbol “HTFL.”
Positive
Seeking Alpha
1 day ago
HeartFlow: Investors Put Their Heart In
HeartFlow's AI-driven, non-invasive CAD diagnostic platform addresses a large, growing market with significant clinical need and strong early adoption. The IPO valued HeartFlow at $1.5 billion, equal to 7 times sales, amidst rapid growth but substantial losses. Operating valuations have been pushed over $2 billion, following a big jump on the opening day of trading.
Positive
Barrons
3 days ago
Heartflow Stock Opens Nearly 50% Above IPO Price in Latest Hot Debut
Medical imaging company Heartflow rose nearly 50% on its first day, joining Firefly, Figma, and Circle as big IPO gainers.
Positive
Reuters
3 days ago
Medtech firm Heartflow gains 47% in solid Nasdaq debut
Shares of Heartflow rose nearly 47.4% in their Nasdaq debut on Friday, valuing the medical technology company at $2.27 billion.
Positive
Reuters
4 days ago
Medtech firm Heartflow raises $316.7 million in US IPO
Medical technology firm Heartflow said on Thursday it has raised $316.7 million in its U.S. initial public offering.
Neutral
GlobeNewsWire
4 days ago
Heartflow, Inc. Announces Pricing of Upsized Initial Public Offering
MOUNTAIN VIEW, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the pricing of its upsized initial public offering of 16,666,667 shares of its common stock at a public offering price of $19.00 per share. All of the shares of common stock are being offered by Heartflow. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Heartflow, are expected to be approximately $316.7 million. In addition, Heartflow has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on August 8, 2025 under the ticker symbol "HTFL.” The closing of the offering is expected to occur on August 11, 2025, subject to the satisfaction of customary closing conditions.
Positive
Reuters
5 days ago
Bain Capital-backed Heartflow targets $1.5 billion valuation in upsized US IPO
Medical technology company Heartflow said on Wednesday it was targeting a valuation of up to $1.46 billion in its upsized initial public offering in the United States, indicating robust investor demand.
Positive
Fast Company
6 days ago
Heartflow stock listing and IPO date draw near: AI-powered medtech aims for $1.3 billion valuation
It seems there's fresh blood pumping back into the IPO market. After a blowout initial public offering from Figma last week, investors might have another chance to get their heart rates up again soon.
Positive
Reuters
1 week ago
Bain Capital-backed Heartflow eyes $1.3 billion valuation in US IPO
Healthcare firm Heartflow said on Friday it was targeting a valuation of up to $1.32 billion in its initial public offering in the United States.
Neutral
GlobeNewsWire
2 weeks ago
Heartflow Plaque Analysis to be Covered by UnitedHealthcare Plans Nationwide
Largest commercial insurer in the United States releases positive comprehensive coverage for AI-enabled Heartflow Plaque Analysis to support precise diagnosis and management of patients Largest commercial insurer in the United States releases positive comprehensive coverage for AI-enabled Heartflow Plaque Analysis to support precise diagnosis and management of patients
Charts implemented using Lightweight Charts™